Axon Enterprise, Inc. (NASDAQ:AXON) Shares Acquired by Captrust Financial Advisors

Captrust Financial Advisors grew its stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 19.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,821 shares of the biotechnology company's stock after buying an additional 2,415 shares during the period. Captrust Financial Advisors' holdings in Axon Enterprise were worth $8,809,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. New Wave Wealth Advisors LLC acquired a new stake in Axon Enterprise during the 4th quarter worth about $40,000. Y.D. More Investments Ltd acquired a new position in shares of Axon Enterprise in the 4th quarter valued at $45,000. Stonebridge Financial Group LLC acquired a new position in Axon Enterprise in the 4th quarter worth about $53,000. GPS Wealth Strategies Group LLC increased its position in shares of Axon Enterprise by 74.1% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after buying an additional 40 shares in the last quarter. Finally, Berbice Capital Management LLC acquired a new position in shares of Axon Enterprise during the 4th quarter worth approximately $59,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the transaction, the chief executive officer now owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. This trade represents a 0.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeri Williams sold 307 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the completion of the sale, the director now directly owns 1,627 shares in the company, valued at $899,275.44. This trade represents a 15.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.40% of the company's stock.

Axon Enterprise Trading Down 0.3 %

Shares of AXON stock traded down $2.24 on Friday, hitting $684.59. 642,401 shares of the stock traded hands, compared to its average volume of 764,683. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a twelve month low of $273.52 and a twelve month high of $715.99. The firm's 50-day moving average price is $564.50 and its two-hundred day moving average price is $584.84. The stock has a market capitalization of $53.29 billion, a PE ratio of 176.90, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter last year, the firm earned $1.15 EPS. The business's revenue was up 31.3% compared to the same quarter last year. As a group, analysts anticipate that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on AXON shares. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Barclays boosted their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday. Needham & Company LLC raised their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday. JMP Securities reissued an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Finally, Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $640.91.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.